ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,505.00
-0.71%
US Tech 100
19,141.20
0.69%
Dow Jones
40,287.53
-0.93%
Brent Oil
81.765
-0.63%
Bitcoin
67,414.48
-1.09%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Merus NV (MRUS)

  7. Merus NV (MRUS) News

MRUS

Merus NV (MRUS)

Merus NV
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MRUS
DateTimeSourceHeadlineSymbolCompany
07/08/20248:00AMGlobeNewswire Inc.Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRCNASDAQ:MRUSMerus NV
07/01/20248:00AMGlobeNewswire Inc.Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical OfficerNASDAQ:MRUSMerus NV
06/17/20243:37PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MRUSMerus NV
06/12/20245:02PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
06/06/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
06/03/20242:30PMGlobeNewswire Inc.Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual MeetingNASDAQ:MRUSMerus NV
06/02/202412:30PMGlobeNewswire Inc.Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual MeetingNASDAQ:MRUSMerus NV
05/30/20245:21PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MRUSMerus NV
05/29/20249:30PMGlobeNewswire Inc.Merus Announces Pricing of Upsized Public Offering of Common SharesNASDAQ:MRUSMerus NV
05/29/20248:00AMGlobeNewswire Inc.Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare ConferenceNASDAQ:MRUSMerus NV
05/28/20244:29PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MRUSMerus NV
05/28/20244:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRUSMerus NV
05/28/20244:01PMGlobeNewswire Inc.Merus N.V. Announces Proposed Public Offering of Common SharesNASDAQ:MRUSMerus NV
05/28/20247:00AMGlobeNewswire Inc.Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCCNASDAQ:MRUSMerus NV
05/23/20245:00PMGlobeNewswire Inc.Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual MeetingNASDAQ:MRUSMerus NV
05/13/20248:00AMGlobeNewswire Inc.Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDANASDAQ:MRUSMerus NV
05/10/20244:33PMEdgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:MRUSMerus NV
05/09/20244:35PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
05/09/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
05/09/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
05/09/20244:30PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MRUSMerus NV
05/09/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
05/09/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
05/09/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
05/09/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
05/08/20244:15PMGlobeNewswire Inc.Merus Announces Financial Results for the First Quarter 2024 and Provides Business UpdateNASDAQ:MRUSMerus NV
05/08/20248:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRUSMerus NV
05/06/20244:05PMGlobeNewswire Inc.Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDACNASDAQ:MRUSMerus NV
04/08/202412:00PMGlobeNewswire Inc.Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024NASDAQ:MRUSMerus NV
04/03/20248:00AMGlobeNewswire Inc.Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:MRUSMerus NV
 Showing the most relevant articles for your search:NASDAQ:MRUS

Your Recent History

USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
HIRU
Hiru (PK)
USOTC
BIEL
Bioelectronics (PK)
USOTC
SPZI
Spooz (PK)
USOTC
RONN
Ronn Motor (PK)
USOTC
VPLM
Voip Pal Com (QB)
COIN
BTCUSD
Bitcoin
NASDAQ
COOP
Mr Cooper
NASDAQ
AVXL
Anavex Life Sciences
NASDAQ
LWLG
Lightwave Logic
USOTC
DBMM
Digital Brand Media and ... (PK)
USOTC
NWBO
Northwest Biotherapeutics (QB)
USOTC
NSAV
Net Savings Link (PK)
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
USOTC
FNMA
Fannie Mae (QB)
USOTC
AXXA
Exxe (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved